What 6 Analyst Ratings Have To Say About Structure Therapeutics
Portfolio Pulse from Benzinga Insights
Structure Therapeutics (NASDAQ:GPCR) received 6 analyst ratings in the last quarter, with an average price target of $88.17, representing significant upside from the current price of $50.4. The consensus among analysts is positive, with 1 bullish and 5 somewhat bullish ratings. The average price target has increased by 48.94% from the previous target of $59.20.
November 15, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Structure Therapeutics has received a strong consensus rating from analysts, with a significant potential upside based on the average price target of $88.17 compared to its current price.
The unanimous positive ratings from analysts, combined with a substantial increase in the average price target, suggest a strong bullish sentiment for GPCR in the short term. This could lead to increased investor interest and a potential rise in the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100